Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

Authors

Keywords

Journal

Volume 62, Issue 1, Pages 173-180

Publisher

Springer Nature

Online

2008-01-22

DOI

10.1007/s00280-007-0665-7

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started